Results 111 to 120 of about 3,638 (152)

Systemic metabolic reprogramming and microbial dysbiosis in Fabry disease: Multi-omics mechanisms and implications for drug development. [PDF]

Front Pharmacol
Gómez-Cebrián N, Trull MC, Gras-Colomer E, Edo Solsona MD, Poveda Andrés JL, Puchades-Carrasco L.   +5 more
europepmc   +1 more source

Nanomedicines for DNA and interference RNA co-delivery: Combined gene therapy for Fabry disease. [PDF]

Int J Pharm X
Beraza-Millor M, Fernández-Muro P, Arribas-Galarreta M, Del Pozo-Rodríguez A, Rodríguez-Gascón A, Solinís MÁ.   +5 more
europepmc   +1 more source

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease.

PLoS ONE, 2012
Mehdi Namdar, Catherine Gebhard, Rafael Studiger, Yi Shi, Pavani Mocharla, Christian Schmied, Pedro Brugada, Thomas F. Lüscher, Giovanni G. Camici   +8 more
doaj   +1 more source

How should kidney injury in Fabry disease be assessed and monitored? [PDF]

Kidney Res Clin Pract
Song SH.
europepmc   +1 more source

Misprocessing of α -Galactosidase A, Endoplasmic Reticulum Stress, and the Unfolded Protein Response. [PDF]

J Am Soc Nephrol
Živná M, Živná M, Dostálová G, Barešová V, Mušálková D, Svojšová K, Meiseles D, Kinstlinger S, Kuchař L, Asfaw B, Poupětová H, Vlášková H, Kmochová T, Vyleťal P, Hartmannová H, Hodaňová K, Stránecký V, Steiner-Mrázová L, Hnízda A, Živný J, Radina M, Votruba M, Sovová J, Trešlová H, Stolnaja L, Reková P, Roblová L, Honsová E, Rychlík I, Dvela-Levitt M, Bleyer AJ, Linhart A, Sikora J, Kmoch S.   +33 more
europepmc   +1 more source

Cardiac manifestations of Fabry disease. [PDF]

NPJ Cardiovasc Health
Dougherty S, Germain DP, Oudit GY, Li A, Leung SP, Zhao CX, Lee A.   +6 more
europepmc   +1 more source

The Role of Kidney Biopsy in Fabry Disease. [PDF]

Biomedicines
Capelli I, Martano L, Berti GM, Vischini G, Lerario S, Donadio V, Incensi A, Aiello V, Ciurli F, Fabbrizio B, Chilotti S, Mignani R, Pasquinelli G, La Manna G.   +13 more
europepmc   +1 more source

Eliglustat prevents acute kidney injury caused by Shiga toxin 2 in lethal and sublethal rat models of hemolytic uremic syndrome. [PDF]

Front Pharmacol
Sánchez DS, Fischer Sigel LK, Zotta E, Silberstein C.   +3 more
europepmc   +1 more source

Lyso-Gb3 in a Fabry pediatric cohort diagnosed by newborn screening. [PDF]

Genet Med Open
Burlina AP, Gragnaniello V, Edini C, Salviati L, Polo G, Porcù E, Meloni N, Cazzorla C, Germain DP, Burlina AB.   +9 more
europepmc   +1 more source

Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension. [PDF]

Nat Commun
Nordbeck P, Goker-Alpan O, Bernat JA, Germain DP, Giraldo P, Jovanovic A, Kimonis V, Nicholls K, Rockman-Greenberg C, Schiffmann R, Thomas M, Tylki-Szymanska A, Wallace E, Welford RWD, West ML, Clozel M, Frey A, Trokan L, Mueller MS, Vogler M, Wanner C, Hughes D.   +21 more
europepmc   +1 more source